Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 303, Issue 1, 2012, Pages

  Camilleri, Michael ^a   Vazquez Roque, Maria ^a   Iturrino, Johanna ^a   Boldingh, Amy ^a   Burton, Duane ^a   McKinzie, Sanna ^a   Wong, Banny S ^a   Rao, Archana S ^a   Kenny, Enda ^b   Månsson, Maria ^b   Zinsmeister, Alan R ^c  

^a Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

^b Rose Pharma A/S   (Denmark)

^c Mayo Clinic   (United States)

Author keywords

Colonic motility; Gastric emptying

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; PLACEBO; ROSE 010; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GASTROINTESTINAL MOTILITY; HUMAN; INTESTINE FUNCTION; IRRITABLE COLON; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH EMPTYING; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CONSTIPATION; DEFECATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL AGENTS; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; GLUCAGON-LIKE PEPTIDE 1; HUMANS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; PAIN MEASUREMENT; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS; RECEPTORS, GLUCAGON; SODIUM PERTECHNETATE TC 99M; STOMACH; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 84863513491     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00076.2012     Document Type: Article

References (45)

1. Amato A, Cinci L, Rotondo A, Faussone-Pellegrini MS, Vannucchi MG, Mulè F. Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil 22: 664-e203, 2010.
2. Andrews CN, Bharucha AE, Camilleri M, Low PA, Seide B, Burton D, Baxter K, Zinsmeister AR. Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults. Am J Physiol Gastrointest Liver Physiol 292: G1359-G1365, 2007.
3. Ayachi SE, Borie F, Magous R, Sasaki K, le Nguyen D, Bali JP, Millat B, Jarrousse C. Contraction induced by glicentin on smooth muscle cells from the human colon is abolished by exendin (9-39). Neurogastroenterol Motil 17: 302-309, 2005.
4. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1 (7-36) amide in rats. Am J Physiol Endocrinol Metab 266: E459-E466, 1994.
5. Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR, Low PA. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 295: R874-R880, 2008.
6. Bouras EP, Delgado-Aros S, Camilleri M, Castillo EJ, Burton DD, Thomforde GM, Chial HJ. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Gut 51: 781-786, 2002.
7. Breen M, Camilleri M, Burton D, Zinsmeister AR. Performance characteristics of the measurement of gastric volume using single photon emission computed tomography. Neurogastroenterol Motil 23: 308-315, 2011.
8. Brubaker PL, Drucker DJ, Asa SL, Swallow C, Redston M, Greenberg GR. Prolonged gastrointestinal transit in a patient with a glucagonlike peptide (GLP)-1-and-2-producing neuroendocrine tumor. J Clin Endocrinol Metab 87: 3078-3083, 2002.
9. Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 38: 1807-1810, 1997.
10. Camilleri M. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clin Pharmacol Ther 91: 44-59, 2012.
11. Camilleri M. Integrated upper gastrointestinal response to food intake. Gastroenterology 131: 640-658, 2006.
12. Camilleri M, Colemont LJ, Phillips SF, Brown ML, Thomforde GM, Chapman N, Zinsmeister AR. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol Gastrointest Liver Physiol 257: G284-G290, 1989.
13. Camilleri M, McKinzie S, Busciglio I, Low PA, Sweetser S, Burton D, Baxter K, Ryks M, Zinsmeister AR. Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 6: 772-781, 2008.
14. Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 103: 36-42, 1992.
15. Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 36: 609-615, 1991.
16. Connell AM. The motility of the pelvic colon. II. Paradoxical motility in diarrhoea and constipation. Gut 3: 342-348, 1962.
17. Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 16: 1781-1790, 2002.
18. Deiteren A, Camilleri M, Bharucha AE, Burton D, McKinzie S, Rao AS, Zinsmeister AR. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 22: 415-423, 2010.
19. Delgado-Aros S, Kim DY, Burton DD, Thomforde GM, Stephens D, Brinkmann BH, Vella A, Camilleri M. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol 282: G424-G431, 2002.
20. Delgado-Aros S, Locke GR 3rd, Camilleri M, Talley NJ, Fett S, Zinsmeister AR, Melton LJ 3rd. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 99: 1801-1806, 2004.
21. De Schepper H, Camilleri M, Cremonini F, Foxx-Orenstein A, Burton D. Comparison of gastric volumes in response to isocaloric liquid and mixed meals in humans. Neurogastroenterol Motil 16: 567-573, 2004.
22. Hasler WL, Saad RJ, Rao SS, Wilding GE, Parkman HP, Koch KL, McCallum RW, Kuo B, Sarosiek I, Sitrin MD, Semler JR, Chey WD. Heightened colon motor activity measured by a wireless capsule in patients with constipation: relation to colon transit and IBS. Am J Physiol Gastrointest Liver Physiol 297: G1107-G1114, 2009.
23. Hellström PM. GLP-1: broadening the incretin concept to involve gut motility. Regul Pept 156: 9-12, 2009.
24. Hellstrom PM, Gryback P, Jacobsson H. The physiology of gastric emptying. Best Pract Res Clin Anaesthesiol 20: 397-407, 2006.
25. Hellström PM, Hein J, Bytzer P, Björnssön E, Kristensen J, Schambye H. Clinical trial: the GLP-1 analogue ROSE-101 for management of acute pain in patients with irritable bowel syndrome: a randomised, placebo-controlled, double-blind study. Aliment Pharmacol Ther 29: 198-206, 2009.
26. Hellstrom PM, Naslund E, Edholm T, Schmidt PT, Kristensen J, Theodorsson E, Holst JJ, Efendic S. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 20: 649-659, 2008.
27. Holz GG, Chepurny OG. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 10: 2471-2483, 2003.
28. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 92: 1885-1893, 1987.
29. Kim DY, Delgado-Aros S, Camilleri M, Samsom M, Murray JA, O'Connor MK, Brinkmann BH, Stephens DA, Lighvani SS, Burton DD. Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol 96: 3099-3105, 2001.
30. Levy RL, Linde JA, Feld KA, Crowell MD, Jeffery RW. The association of gastrointestinal symptoms with weight, diet, and exercise in weight-loss program participants. Clin Gastroenterol Hepatol 3: 992-996, 2005.
31. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32: 920-924, 1997.
32. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. In: Rome III: The Functional Gastrointestinal Disorders (3rd ed.), edited by Drossman DA, Corazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, Whitehead WE, and the Rome III Committees. McLean, VA: Degnon Associates, 2006.
33. Manabe N, Wong BS, Camilleri M, Burton D, McKinzie S, Zinsmeister AR. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 22: 293-e82, 2010.
34. Nakade Y, Tsukamoto K, Iwa M, Pappas TN, Takahashi T. Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats. Auton Neurosci 131: 50-56, 2007.
35. Nakade Y, Tsukamoto K, Pappas TN, Takahashi T. Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. Brain Res 1111: 117-121, 2006.
36. Naslund E, Bogefors J, Skogar S, Grybäck P, Jacobsson H, Holst JJ, Hellström PM. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol Regul Integr Comp Physiol 277: R910-R916, 1999.
37. Nullens S, Nelsen T, Camilleri M, Burton D, Eckert D, Iturrino J, Vazquez-Roque M, Zinsmeister AR. Regional colon transit in patients with dyssynergic defecation or slow transit in patients with constipation. Gut. In press.
38. Patterson B, Trautmann M, Mace K. The pharmacokinetics and pharmacodynamics of LY307161SR, a sustained release formulation of a GLP analogue administered subcutaneously to patients with type 2 diabetes (Abstract). Diabetologia 45: A43, 2002.
39. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipationpredominant irritable bowel syndrome. Gastroenterology 118: 463-468, 2000.
40. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev Oct 5: CD006423, 2011.
41. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellström PM. Glucagonlike peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 43: 2284-2290, 1998.
42. Trautmann M, Kapitza C, Mace K. LY307161SR a sustained release formulation of a GLP-1 analog is suitable for once daily administration in patients with type 2 diabetes (Abstract). Diabetes Forecast 51: A135, 2002.
43. Vella A, Bock G, Giesler PD, Burton DB, Serra DB, Saylan ML, Deacon CF, Foley JE, Rizza RA, Camilleri M. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation, and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study. Clin Endocrinol (Oxf) 69: 737-744, 2008.
44. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, Hollenberg AN, Baggio L, Saper CB, Drucker DJ, Elmquist JK. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 110: 43-52, 2002.
45. Yu BS, Wang AR. Glucagon-like peptide 1 based therapy for type 2 diabetes. World J Pediatr 4: 8-13, 2008.